This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cerus Announces FDA Agreement On Modular Premarket Approval Application (PMA) Submission Process For INTERCEPT Plasma

Cerus Corporation (NASDAQ: CERS) announced today that the U.S. Food and Drug Administration (FDA) has accepted its proposed modular Premarket Approval application (PMA) shell for review of the INTERCEPT Blood System for plasma. A PMA shell is an outline of the application process that defines the structure, content and timing of each module. FDA and the applicant need to agree on a shell prior to initiation of a modular PMA submission.

”Our PMA shell proposal was designed to leverage our existing regulatory dossier from European approvals and to begin the INTERCEPT plasma regulatory submission in Q1 of 2013,” said Carol Moore, Cerus’ vice president, regulatory affairs, quality and clinical. “FDA’s agreement with our proposal means that we can target completing all four modules in 2013, putting us in a position to receive U.S. approval as early as 2014.”

A modular PMA review process is based on submission of a compilation of sections or "modules" at 90-day intervals that together become a complete PMA. Under a modular approach, FDA is able to review each module separately, allowing the applicant to receive timely feedback and potentially resolve deficiencies earlier in the review process than would be expected with a traditional PMA application.

Cerus recently announced its intention to pursue a modular PMA submission after dialogue with the FDA indicated that the company could proceed with an application for multiple indications of plasma use, not just the thrombotic thrombocytopenic purpura (TTP) indication for which Cerus received orphan drug designation last year.

“Approval in the U.S. would be a pivotal achievement for us,” said Cerus' president and CEO, William ‘Obi’ Greenman. "We have already begun launch planning activities for the U.S., benefiting from our many years of experience in Europe commercializing the INTERCEPT Blood System and working with INTERCEPT plasma customers."

The INTERCEPT Blood System for plasma received a CE mark in 2006, with subsequent national approvals in France, Germany and Switzerland. In clinical trials in patients with acquired coagulopathies, congenital coagulopathies and TTP, INTERCEPT plasma was well tolerated and demonstrated therapeutic efficacy comparable to conventional plasma. Data have also been collected in Phase IV studies and hemovigilance programs that support the safety and efficacy of INTERCEPT plasma in routine use across a broad variety of indications. INTERCEPT plasma is currently used by customers in Belgium, France, Germany, Italy, Kazakhstan, Russia and Spain.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs